Home >> Expert Review of Pharmacoeconomics and Outcomes Research, Volume 4, Number 6

Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD

Authors: Narayan, Sangeeta; Hay, Joel

Source: Expert Review of Pharmacoeconomics and Outcomes Research, Volume 4, Number 6, December 2004 , pp. 625-634(10)

Publisher: Expert Reviews

Buy & download fulltext article:

OR

Price: $73.00 plus tax (Refund Policy)

Abstract:

Although it is widely accepted that stimulants are used as the treatment of choice in attention deficit hyperactivity disorder, many decision makers do not have appropriate information regarding an optimal first-line agent in treating this patient population. The cost effectiveness in choosing methylphenidate (Ritalin®®) or amphetamine/ dextroamphetamine mixed salts (Adderall®®) as a first-line agent in the treatment of attention deficit hyperactivity disorder is evaluated. This report uses decision-tree analysis to evaluate the cost effectiveness of basing decisions on three treatment arms: initiation with methylphenidate, initiation with amphetamine/dextroamphetamine or no treatment. Data inputs such as efficacy rates, side effects, compliance rates and school administration rates were extracted from a literature review. A societal perspective was used to estimate outcomes in terms of incremental cost and incremental utilities over the time horizon of 1 year.
More about this publication?
Related content
Marked list

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
^ Back to top
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page